Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 198.29% | 36.56% | -49.85% | 94.11% | -94.47% |
| Depreciation & Amortization | -47.24% | -9.23% | -60.85% | -26.35% | 149.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.56% | 22.87% | -48.87% | -25.61% | -92.62% |
| Operating Income | -133.56% | -22.87% | 48.87% | 25.61% | 92.62% |
| Income Before Tax | -89.81% | -14.72% | 15.02% | 32.65% | 90.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -89.81% | -14.72% | 15.02% | 32.65% | 90.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -89.81% | -14.72% | 15.02% | 32.65% | 90.60% |
| EBIT | -133.56% | -22.87% | 48.87% | 25.61% | 92.62% |
| EBITDA | -139.14% | -25.53% | 48.55% | 26.12% | 92.84% |
| EPS Basic | -58.87% | 5.10% | 29.49% | 38.91% | 91.06% |
| Normalized Basic EPS | -57.69% | 4.92% | 34.07% | 28.99% | 91.00% |
| EPS Diluted | -58.87% | 5.10% | 29.49% | 38.91% | 91.06% |
| Normalized Diluted EPS | -57.69% | 4.92% | 34.07% | 28.99% | 91.00% |
| Average Basic Shares Outstanding | 19.82% | 20.18% | 20.23% | 10.32% | 4.76% |
| Average Diluted Shares Outstanding | 19.82% | 20.18% | 20.23% | 10.32% | 4.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |